fig6

Synergistic inhibition of SCR1- and ERBB2-driven brain metastatic breast cancer cells

Figure 6. Inhibition of BBM1 cell proliferation upon treatment with a GABA agonist alone and in combination with ERBB2 or SRC inhibitors. A: BBM1cells were treated with GABA agonist Isoguvacine, AC-93253, and/or Lapatinib at final concentrations of 100 nmol/L. The percentages of viable cells in each treatment group relative to viable control cells treated with DMSO are shown for data collected after 48 h (n = 3, P < 0.05). Error bars indicate SEM; B: the induction of apoptosis was measured using Annexin V-FITC staining followed by FACS analysis. Control cells were treated with DMSO alone; C: hierarchical clustering based on the expression GABA receptors and subunits in primary breast cancer (PT1-2), breast to brain metastatic tumor tissue (MT1-3), normal breast tissue (nBreast), and normal brain tissue (nBrain). Low expression (blue), high expression (red)

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/